Observational studyCancer research and treatment2024

First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World Data.

Youngkyung Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.